Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963097 | 0.80 | GPR3 (0.54) | CYP1A2GPR3MAPTPTPN7DUSP3 | |
| SCHEMBL31081432 | 0.80 | GPR3 (0.54) | CYP1A2GPR3MAPTPTPN7DUSP3 | |
| SCHEMBL7821341 | 0.79 | CYP1A2 (0.62) | CYP1A2GPR3MAPTPTPN7DUSP3 | |
| SCHEMBL19768707 | 0.78 | GPR3 (0.56) | CYP1A2GPR3MAPTPTPN7DUSP3 | |
| SCHEMBL11232390 | 0.78 | AKR1B1 (0.53) | CYP1A2GPR3MAPTALDH1A1HPGD | |
| SCHEMBL31113417 | 0.78 | AKR1B1 (0.56) | CYP1A2MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL14299543 | 0.78 | AKR1B1 (0.56) | CYP1A2MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL18903328 | 0.77 | GPR3 (0.50) | CYP1A2GPR3MAPTPTPN7DUSP3 | |
| Methane SCHEMBL11248449 | 0.77 | AKR1B1 (0.51) | CYP1A2GPR3MAPTALDH1A1HPGD | |
| SCHEMBL12075019 | 0.77 | GPR3 (0.54) | CYP1A2GPR3MAPTPTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | Neuberger, Timothy | 2008-03-20 | — | — | US | disclosed |
| US-7271187-B2 | Compositions and methods for promoting tissue regeneration | Neuberger, Tim (US) | 2007-09-18 | — | — | US | disclosed |
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | URI HERZBERG | 2002-05-09 | — | — | US | disclosed |
| WO-2001076592-A1 | COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION | ACORDA THERAPEUTICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-4965284-A | IMMUNOMODULATORS | AMERICAN CYANAMID COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0342433-A2 | Substituted dibenzothiaphenes | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055530-A1 | Compositions and methods for promoting tissue regeneration | TST, DCX, GAP43 | CYP1A2 3169/4885GPR3 2745/4885MAPT 1089/4885 |
| US-20080070963-A1 | Compositions and methods for promoting neural regeneration | GAP43, DCX, BDNF | CYP1A2 3970/4885GPR3 2839/4885MAPT 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.